ArticleAntimicrobial agents and chemotherapy2021
Point Mutation or Overexpression of Aspergillus fumigatus
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Antifungal resistance: from classical mechanisms to the expanding role of acetyltransferases.Journal of biomedical science · 2026Review
- Directed evolution of the pathogenic moldAntimicrobial agents and chemotherapy · 2026Article
- Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026Review
- Article
- Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Epidemiology, antifungal susceptibility and biological characteristics of clinical Aspergillus fumigatus in a tertiary hospital.Scientific reports · 2025Article
- Activity of Azole and Non-Azole Substances AgainstInternational journal of molecular sciences · 2025Article
- From crops to clinic: the impact of dual azole use on antifungal resistance inFrontiers in microbiology · 2025Review
- Commercial Methods for Antifungal Susceptibility Testing of Saprophytic Molds: Can They Be Used to Detect Resistance?Journal of fungi (Basel, Switzerland) · 2024Review
- Isolation of triazole-resistantMycology · 2024Article
- Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.Frontiers in microbiology · 2024Review
- Epidemiology and Azole Resistance of Clinical Isolates ofInfection and drug resistance · 2024Article
- Efficient Generation of Multiple Seamless Point Mutations Conferring Triazole Resistance inJournal of fungi (Basel, Switzerland) · 2023Article
- Comparative analysis of the biological characteristics and mechanisms of azole resistance of clinicalFrontiers in microbiology · 2023Article
- Molecular mechanisms governing antifungal drug resistance.npj antimicrobials and resistance · 2023Review
- Characterization and engineering of the xylose-inducibleMetabolic engineering communications · 2022Article
- Deletion ofAntimicrobial agents and chemotherapy · 2022Article
- Review on Plant-Based Management in Combating Antimicrobial Resistance - Mechanistic Perspective.Frontiers in pharmacology · 2022Review
- Are Point Mutations in HMG-CoA Reductases (Hmg1 and Hmg2) a Step towards Azole Resistance inMolecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus fumigatus is the most common cause of invasive fungal mold infections in immunocompromised individuals. Current antifungal treatment relies heavily on the triazole antifungals which inhibit fungal Erg11/Cyp51 activity and subsequent ergosterol biosynthesis. However, resistance, due primarily to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.